Skip to main content
Caplight Logo









Ochre Bio

Ochre Bio

Private
OxfordHealthcare & Life Scienceshttps://www.ochre-bio.com/

Last Round

Series A

Oct 10, 2022

Total Funding Raised

$39.75M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Ochre Bio is a biotechnology company that develops RNA-based therapies for chronic liver diseases using a discovery platform that integrates machine learning, genomic phenotyping, and perfused human donor livers.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Application

Keywords

drug discoveryliver therapeuticsfunctional genomicsin silico drug discoveryRNA therapeuticsAI drug discoveryhuman primary celltarget identificationnext-gen sequencingbiotech platformdata as a serviceDaaScomputational biologytechbioAI-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ochre Bio Comparables

Compare Ochre Bio with similar companies based on industry and business-model similarity.

Ochre Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Multiomic Health
75%
Quotient Therapeutics
75%
Insitro
70%

Ochre Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 10, 2022
SeedJun 16, 2021
Pre SeedMar 18, 2020

Key People

Founding team and executive leadership

Quin Wills

Founder and CEO

Founding Team

Ochre Bio Investors

Notable investors and investment history

Ochre Bio investors
InvestorRounds
Backed VCSeries A, Seed
LifeLink VenturesSeries A
Khosla VenturesSeries A, Seed
Hoxton VenturesSeed
Hermes-EpitekSeries A, Seed
Lifeforce CapitalSeries A
EIT HealthSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 24, 2026

    Monthly visitors grew 34% MoM, reaching 4.4K.

  • Jun 30, 2025

    Quin Wills appointed as the new Chief Executive Officer.

Ochre Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ochre Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ochre Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersOxford
Employee Range60
Year Founded2019
Last FundingOct 10, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?